# Where Cannabinoid Receptors Actually Live: A Working Map of CB1 and CB2 Across the Human Body > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cb1-and-cb2-receptor-distribution-in-the-body/ > **Published:** 2026-09-04T22:55:45-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:39:27-04:00 > **Clinical Summary:** CB1 and CB2 receptor distribution across brain and immune tissue, from the primary human data, plus where receptor pharmacology is still contested. --- CED Clinical Relevance #61Foundational ReferenceNearly every clinical question in cannabis medicine, from why inhaled THC changes heart rate to why CBD does not feel like much of anything, traces back to which receptor sits where. This page is the anatomical reference the rest of the site leans on. The endocannabinoid system gets described in brochures as a network that keeps the body in balance. That is not wrong, but it is not useful. What is useful is knowing which receptor is expressed in which tissue, at what density, measured how, and how confident the field actually is about each claim. Clinical Insight | CED Clinic Two cannabinoid receptors have been cloned and formally classified: CB1, reported by Matsuda and colleagues in *Nature* in 1990, and CB2, reported by Munro and colleagues in *Nature* in 1993. They share roughly 48 percent amino acid sequence identity and both signal through inhibitory G proteins, according to the International Union of Pharmacology classification published in *Pharmacological Reviews* in 2002. CB1 is the most abundant G protein-coupled receptor in large parts of the mammalian brain and is also present, at far lower levels, in a long list of peripheral tissues. CB2 is concentrated in immune cells and lymphoid tissue. That division is real, but it is a gradient rather than a wall, and the exceptions are where most of the current scientific argument lives. Endocannabinoid SystemCB1 ReceptorCB2 ReceptorReceptor PharmacologyCannabis Science AudiencePatients, caregivers, and cliniciansPrimary TopicCB1 and CB2 cannabinoid receptor distribution and physiological rolesSource[Read the full source](https://doi.org/10.1124/pr.54.2.161) Why This Matters Receptor location explains clinical behavior. CB1 density is high in the basal ganglia, hippocampus and cerebellum and low in the brainstem nuclei that run breathing and circulation, which is the anatomical reason a large dose of THC produces disorientation and tachycardia rather than respiratory arrest. Herkenham and colleagues made exactly that point in the 1990 paper that first mapped the receptor. It also explains the limits. A patient who reads that CB2 receptors regulate inflammation and concludes that a CB2-targeted product will treat their arthritis has skipped several steps, because expression of a receptor in a tissue is not evidence that a drug acting on it changes a clinical outcome. What Was Cloned, and What That Settled CB1 came first. L. A. Matsuda and colleagues at the National Institute of Mental Health cloned a complementary DNA encoding a G protein-coupled receptor that inhibited adenylate cyclase in a dose-dependent, stereoselective and pertussis toxin-sensitive manner, and that responded more strongly to psychoactive than to non-psychoactive cannabinoids. The paper appeared in *Nature* on August 9, 1990. CB2 came three years later, from a different direction. Sean Munro and colleagues at the MRC Laboratory of Molecular Biology in Cambridge were looking for a receptor that could explain the non-psychoactive effects of cannabinoids. They found one that was not expressed in brain but was expressed in macrophages in the marginal zone of the spleen, and published it in *Nature* in September 1993. The 2002 International Union of Pharmacology classification, authored by Allyn Howlett with Raphael Mechoulam, Roger Pertwee, Ken Mackie, Miles Herkenham and others, formalized the two-receptor scheme. That document also made a point worth repeating: the committee considered it premature to rename cannabinoid receptors after an endogenous agonist, because it was unclear whether the known endocannabinoids are the only or even the primary natural ligands. Twenty-four years later that caution still reads as correct. The Human CB1 Map, Measured Rather Than Asserted The foundational anatomy comes from autoradiography, meaning a radiolabeled cannabinoid is applied to tissue sections and the binding is photographed. Herkenham and colleagues used tritiated CP 55,940 across several mammalian species including human and reported a conserved distribution: densest in the outflow nuclei of the basal ganglia, specifically the substantia nigra pars reticulata and globus pallidus, and in hippocampus and cerebellum. Michelle Glass, Michael Dragunow and Richard Faull at the University of Auckland did the detailed human work, published in *Neuroscience* in 1997, using quantitative autoradiography on one fetal, two neonatal and eight adult human brains. Their findings are more granular than most summaries admit. Binding was very high in the dentate gyrus, Ammon’s horn and subiculum of the hippocampal formation, high in entorhinal cortex and amygdala, and highest within neocortex in the association areas of the frontal and limbic lobes rather than in primary sensory or motor cortex. Within cortex the labeling followed the laminar architecture, concentrating in a narrow superficial band corresponding to lamina I and a broader deep band corresponding to laminae V and VI. In the midbrain, substantia nigra pars reticulata carried some of the highest densities in the entire brain. The spinal cord, by contrast, showed very low binding. Fetal and neonatal brains showed the same overall pattern at generally higher density, particularly in basal ganglia. CB1 Outside the Brain, Including Inside the Mitochondrion S. Galiegue and colleagues at Sanofi Recherche in Montpellier quantified CB1 and CB2 transcripts across human tissues and leukocyte subpopulations using a sensitive PCR method, publishing in the *European Journal of Biochemistry* in 1995. CB1 was mainly a central nervous system transcript but was detectable at lower levels in adrenal gland, heart, lung, prostate, uterus, ovary, testis, bone marrow, thymus and tonsil. That peripheral presence is the reason cannabinoid effects are not confined to perception. It is also the reason a CB1 blocker turned out to be a systemic drug rather than a brain drug, with consequences discussed further below. One location deserves separate mention because it changed how the field thinks about the receptor. Giovanni Benard, Giovanni Marsicano and colleagues in Bordeaux reported in *Nature Neuroscience* in 2012 that CB1 is present on the membranes of mouse neuronal mitochondria, where activation reduced cyclic AMP concentration, protein kinase A activity, complex I enzymatic activity and respiration. A receptor that regulates cellular energy production from inside the organelle is a different kind of object than a receptor that only sits on the plasma membrane, and this work has not been replicated in human tissue. CB2 and the Immune System, in Rank Order The same 1995 Galiegue study gives the cleanest quantitative picture of CB2 that exists in human tissue. CB2 was not detected in brain. It was abundant in immune tissue, at an expression level 10 to 100 times higher than that of CB1. In spleen and tonsil, CB2 messenger RNA content was equivalent to the CB1 content of the central nervous system, which is a useful way to calibrate what abundant means here. Among human blood cell subpopulations the rank order was B cells, then natural killer cells, then a substantial drop to monocytes, polymorphonuclear neutrophils, CD8 T cells and CD4 T cells. The same ordering held in myeloid, monocytic and lymphoid cell lines. Immunohistology on tonsil sections localized CB2 protein to B-lymphocyte-enriched areas of the mantle of secondary lymphoid follicles, not diffusely across the tissue. Caroline Turcotte and colleagues at Universite Laval reviewed the functional consequences in *Cellular and Molecular Life Sciences* in 2016. The recurring finding across models is that CB2-deficient mice show an exacerbated inflammatory phenotype, which positions CB2 as a brake on immune activation rather than an on switch. Whether that brake can be pressed therapeutically in humans is a separate question that the animal work does not answer. Where the Receptor Pharmacology Is Genuinely Contested The neat division of CB1 in brain and CB2 in immune cells started breaking down in 2005, when Marja Van Sickle, Keith Sharkey and colleagues reported CB2 messenger RNA and protein on brainstem neurons in *Science*. Hai-Ying Zhang and colleagues at the National Institute on Drug Abuse reported in *PNAS* in 2014 that CB2 receptors are expressed in ventral tegmental area dopamine neurons and that a CB2 agonist inhibited their firing, with the effects absent in CB2 knockout mice. Brady Atwood and Ken Mackie titled their 2010 *British Journal of Pharmacology* review *CB2: a cannabinoid receptor with an identity crisis*, and the title was earned. The central problem is technical. In 2018 the Zhang group tested four anti-CB2 antibodies against partial knockout mice and concluded that none of them were highly specific for mouse CB2. Y. Li and J. Kim, using ultrasensitive in situ hybridization in mouse hippocampus in 2015, detected CB2 messenger RNA in subsets of excitatory and inhibitory neurons but rarely in microglia, while noting that immunological detection of the protein remained unreliable. So the honest position is this. CB2 transcripts are detectable in some central neurons. The protein is present at levels low enough that the antibodies available cannot reliably find it. Anyone who tells you confidently that CB2 is or is not a neuronal receptor is ahead of the data. A related open question concerns GPR55, which E. Ryberg and colleagues at AstraZeneca characterized in 2007 as binding and being activated by cannabinoid ligands including anandamide and cannabidiol. It has been proposed as a third cannabinoid receptor, and the international nomenclature committee has not adopted that designation. The Endogenous Ligands and How the System Signals Anandamide, chemically arachidonylethanolamide, was isolated from porcine brain by William Devane, Lumir Hanus and Raphael Mechoulam’s group and reported in *Science* in December 1992. Two independent groups identified 2-arachidonoylglycerol in 1995: Mechoulam’s laboratory found it in canine intestine, and Takayuki Sugiura’s group at Teikyo University identified it in rat brain. The signaling geometry is unusual and worth understanding, because it explains why cannabinoid drugs behave the way they do. Rachel Wilson and Roger Nicoll showed in *Nature* in 2001 that endocannabinoids released by depolarized hippocampal pyramidal neurons travel backward across the synapse to CB1 receptors on presynaptic terminals and suppress transmitter release. Endocannabinoids are not stored in vesicles and released on command. They are synthesized on demand from membrane lipids at the site and moment they are needed, then broken down locally by fatty acid amide hydrolase and monoacylglycerol lipase. That architecture is why the endocannabinoid system behaves like a local dimmer switch rather than a broadcast signal, and why flooding the whole system with an exogenous agonist produces effects that native signaling never would. Evidence SnapshotCB1 cloningMatsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. *Nature* 1990;346(6284):561-4. PMID 2165569CB2 cloningMunro S, Thomas KL, Abu-Shaar M. *Nature* 1993;365(6441):61-5. PMID 7689702Receptor classificationHowlett AC et al. IUPHAR XXVII. *Pharmacol Rev* 2002;54(2):161-202. PMID 12037135Brain receptor mappingHerkenham M et al. *Proc Natl Acad Sci USA* 1990;87(5):1932-6. PMID 2308954Human brain quantificationGlass M, Dragunow M, Faull RL. *Neuroscience* 1997;77(2):299-318. PMID 9472392Human tissue expressionGaliegue S et al. *Eur J Biochem* 1995;232(1):54-61. PMID 7556170Highest CB1 density regionsSubstantia nigra pars reticulata, globus pallidus internus, hippocampal formation, cerebellar molecular layerCB2 rank order in bloodB cells > natural killer cells >> monocytes > neutrophils > CD8 T cells > CD4 T cellsEndogenous ligandsAnandamide: Devane WA et al. *Science* 1992, PMID 1470919. 2-AG: Mechoulam R et al. *Biochem Pharmacol* 1995, PMID 7605349; Sugiura T et al. *Biochem Biophys Res Commun* 1995, PMID 7575630Retrograde signalingWilson RI, Nicoll RA. *Nature* 2001;410(6828):588-92. PMID 11279497Principal open questionWhether CB2 is functionally expressed on central neurons. Atwood BK, Mackie K. *Br J Pharmacol* 2010;160(3):467-79. PMID 20590558 How Strong Is This Evidence? The evidence is not uniform across this page, and it helps to grade it. CB1 localization in the human brain is about as solid as neuroanatomy gets: multiple independent methods, replicated across species, with quantitative human data from Auckland covering fetal through adult tissue. Treat the regional CB1 map as settled. CB2 expression in immune tissue is also well supported, with concordant messenger RNA quantification, Northern blot and immunohistology in the same 1995 study. CB2 in neurons is a different matter entirely: the transcript evidence is reasonable, the protein evidence rests on antibodies that failed specificity testing against knockout tissue in 2018, and the field has not resolved it. Where This Paper Deserves Skepticism Most of the anatomical work here is rodent, and the human data that exist come from small autopsy series. The Glass study, which remains the best quantitative human map, used eight adult brains. That is enough to establish a pattern and not enough to characterize variation between people, which is precisely the variation a clinician cares about when one patient tolerates a dose that floors another. Receptor messenger RNA is not receptor protein, and receptor protein is not receptor function. A great deal of published expression data conflates these three, and the CB2 antibody problem is the clearest illustration of how far wrong that can go. Expression studies also tend to be performed in healthy tissue, while CB2 in particular is inducible and rises during inflammation, so a baseline map understates what is available for a drug to act on in a diseased tissue. What This Paper Does Not Show Nothing on this page shows that cannabis treats any condition. Receptor anatomy establishes where a drug can act, not whether acting there helps. The step from expression map to clinical benefit requires randomized trials, and for most conditions those trials either have not been done or have not been positive. This material also does not support product marketing that assigns specific effects to specific receptors. Claims of the form that a product targets CB2 for inflammation without touching CB1 are not supported by the pharmacology of plant cannabinoids, which bind promiscuously and, in the case of cannabidiol, act substantially through targets other than either receptor. How This Fits With the Broader Clinical Conversation The most instructive episode in this field is rimonabant. A selective CB1 blocker was developed for obesity, worked for weight loss, and was withdrawn. Robin Christensen and colleagues pooled four randomized trials totaling 4,105 participants in *The Lancet* in 2007: 20 mg daily produced 4.7 kg more weight loss than placebo at one year, and patients were two and a half times more likely to discontinue for depressive mood disorders. That is what happens when a drug engages a receptor expressed across association cortex and limbic structures. In the other direction, CB1 is not static. Jussi Hirvonen and colleagues at the National Institute of Mental Health used positron emission tomography to show reversible, regionally selective downregulation of cortical CB1 receptors in chronic daily cannabis smokers, with density returning toward normal after roughly four weeks of monitored abstinence, published in *Molecular Psychiatry* in 2012. Receptor anatomy is a map of a system that adapts to what you put into it. Dr. Caplan’s Take I keep coming back to the brainstem finding from 1990, because it answers a question patients ask in almost every consultation. The reason a cannabis overdose is frightening rather than fatal is that the nuclei controlling breathing and blood pressure carry very few CB1 receptors. That single anatomical fact does more to calm a nervous new patient than any amount of reassurance, and it has the advantage of being true. The part I try to be careful about is the opposite direction. Patients hear that receptors are everywhere and conclude that cannabis must therefore do everything. Receptors being present tells you a tissue can respond. It does not tell you the response is beneficial, or that you can steer it with a dispensary product. I would rather a patient leave my office understanding one receptor properly than leave believing a system diagram they cannot use. Clinical Bottom Line CB1 concentrates in basal ganglia outflow nuclei, hippocampus, cerebellum and association cortex, and is sparse in cardiorespiratory brainstem. CB2 concentrates in immune tissue, with B lymphocytes carrying the most. Both receptors appear outside their headline locations, the neuronal CB2 question remains open, and none of this anatomy by itself establishes that any cannabis product treats any condition. What a Careful Reader Should Take Away Read this as a map with variable resolution. The CB1 regions are drawn to high confidence, the CB2 immune distribution to good confidence, and the edges of the map, meaning neuronal CB2, mitochondrial CB1 and GPR55, are sketched in pencil. A page that presents all three at the same confidence level is telling you something other than the truth. Evidence Interpretation Guide Table of Contents - [How to read receptor expression data without over-reading it](#How_to_read_receptor_expression_data_without_over-reading_it) - [Cannabinoid Receptor Anatomy, Seen From Eight Angles](#Cannabinoid_Receptor_Anatomy_Seen_From_Eight_Angles)[What the map does and does not promise](#What_the_map_does_and_does_not_promise) - [Anatomy predicts the adverse effect profile](#Anatomy_predicts_the_adverse_effect_profile) - [Expression data are softer than they look](#Expression_data_are_softer_than_they_look) - [Small human samples, mostly rodent mechanism](#Small_human_samples_mostly_rodent_mechanism) - [Thirty-six years of narrowing and widening](#Thirty-six_years_of_narrowing_and_widening) - [What this changes at the dispensary counter](#What_this_changes_at_the_dispensary_counter) - [The questions worth funding](#The_questions_worth_funding) - [Why receptor language gets abused in marketing](#Why_receptor_language_gets_abused_in_marketing) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to read receptor expression data without over-reading it The Research QuestionWhich tissues express CB1 and CB2 cannabinoid receptors, at what relative density, and by what method was that measured?The Patient QuestionIf these receptors are all over my body, what does that actually mean for whether cannabis will help me?The Bottom LineReceptor distribution explains what cannabinoids can influence and where side effects come from. It does not establish therapeutic benefit for any condition, which requires clinical trials. CED Perspective Lens ## Cannabinoid Receptor Anatomy, Seen From Eight Angles One receptor map, read through the lenses that matter in clinical practice. Lens OverviewCB1 is densest in basal ganglia outflow nuclei, hippocampus, cerebellum and association cortex and sparse in cardiorespiratory brainstem. CB2 is concentrated in immune tissue, with B lymphocytes leading. #### What the map does and does not promise Cannabinoid receptors sit in tissues that handle movement, memory, emotion, appetite, pain signaling and immune regulation. That is why cannabis can affect so many things at once, and why the effects are rarely selective in the way a targeted drug is selective. The practical takeaway is modest and real. Because the brainstem regions controlling breathing carry very few CB1 receptors, taking too much cannabis is unpleasant rather than dangerous in the way an opioid overdose is dangerous. That does not make any dose safe, and it says nothing about whether cannabis helps your particular condition. Lens takeawayReceptors being present in a tissue means cannabis can act there. It does not mean it should. #### Anatomy predicts the adverse effect profile If you know where CB1 is dense, you can predict most of what patients report. High density in basal ganglia and cerebellum maps onto the motor and coordination effects. Hippocampal density maps onto the acute memory effects. Association cortex and amygdala density map onto the cognitive and anxiety effects, and onto the psychiatric signal seen when the receptor is blocked pharmacologically. Sparse brainstem expression is the reason cannabinoid toxicity does not present like opioid toxicity. It is worth saying out loud to patients on chronic opioids who are considering cannabis, as long as you also say that the two together increase sedation risk. Lens takeawayMap the effect the patient describes back to a receptor-dense region and the conversation gets more concrete. #### Expression data are softer than they look Much of what circulates as established receptor anatomy rests on antibody staining, and the cannabinoid field has a documented antibody problem. The 2018 testing of four anti-CB2 antibodies against partial knockout mice found that none were highly specific, and that apparently positive signal could come from truncated receptor protein in the knockouts themselves. Messenger RNA quantification is more reliable for presence and absence but says nothing about how much functional protein reaches the membrane. When a review states that a receptor is expressed somewhere, the useful next question is by which method and with what negative control. Lens takeawayAsk which method produced the claim before you trust the location. #### Small human samples, mostly rodent mechanism The quantitative human brain data rest on eight adult brains from a single 1997 study. It is excellent work and it is not a population sample. Between-person variation in receptor density, which would explain a great deal of the clinical variability physicians see, is essentially uncharacterized in humans. The mitochondrial CB1 finding, which would be important if it generalizes, comes from mouse tissue and has not been demonstrated in human neurons. It belongs in a page like this as an open direction, not as established human physiology. Lens takeawayThe human map is a sketch built from very few brains. #### Thirty-six years of narrowing and widening The field moved from a plausible assumption that cannabinoids worked by nonspecifically disrupting cell membranes, an idea Matsuda’s 1990 paper explicitly set out to test, to a clean two-receptor model by 1993, and then spent the next three decades finding that the clean model leaked at the edges. That trajectory is normal for receptor pharmacology and is not a sign the model is wrong. CB1 and CB2 remain the two classified cannabinoid receptors. What changed is the recognition that they are not confined to the tissues where they were first found, and that other targets participate. Lens takeawayThe two-receptor model held. Its boundaries did not. #### What this changes at the dispensary counter Very little, and that is the point worth making. Plant cannabinoids do not sort themselves neatly by receptor. THC is a partial agonist at both CB1 and CB2. Cannabidiol has low affinity for both and produces most of its effects through other mechanisms entirely. A product marketed as targeting a specific receptor for a specific outcome is making a claim the underlying pharmacology does not support. The variables a patient can actually control are dose, route, timing and cannabinoid ratio, which is where clinical attention belongs. Lens takeawayNo commercially available cannabis product selectively targets one cannabinoid receptor. #### The questions worth funding Three stand out. Whether functional CB2 protein exists on human central neurons, which requires validated detection reagents rather than better antibodies used the same way. Whether mitochondrial CB1 is a human phenomenon. And whether GPR55 warrants formal classification as a cannabinoid receptor. A fourth, less glamorous question matters more clinically: how much CB1 density varies between healthy people, and whether that variation predicts who responds to cannabinoid therapy and who has a bad time with it. Lens takeawayBetter reagents and human receptor imaging, not more rodent expression papers. #### Why receptor language gets abused in marketing Endocannabinoid system diagrams have become a marketing asset. A body outline with receptors labeled across every organ implies a therapeutic reach that no trial evidence supports, and it is effective precisely because the underlying anatomy is real. Regulators have largely treated cannabinoid product claims as a labeling problem. The deeper issue is that accurate biology is being used to imply inaccurate clinical conclusions, which is harder to police than a false ingredient list. Lens takeawayTrue anatomy is being used to sell untested benefit, and that gap is where oversight is thin. Related Reading at CED ClinicContinue exploring the evidence[Two Molecules, Two Routes: How the Body Handles THC and CBD Differently](https://cedclinic.com/thc-and-cbd-metabolism-pathways-compared/) Once cannabinoids reach these receptors, the liver determines how long they stay. This is the metabolic half of the picture. [Follow the metabolism](https://cedclinic.com/thc-and-cbd-metabolism-pathways-compared/)[Study Identifies Molecular Mechanism Behind Cannabinoid Tolerance](https://cedclinic.com/study-identifies-molecular-mechanism-behind-cannabinoid-tolerance/) Receptor density is not fixed. This covers what repeated exposure does to CB1 signaling over time. [See the tolerance evidence](https://cedclinic.com/study-identifies-molecular-mechanism-behind-cannabinoid-tolerance/)[CBG, CBN, CBC, and THCV: Which Cannabinoid Claims Come From Human Studies](https://cedclinic.com/minor-cannabinoids-human-evidence/) Minor cannabinoids interact with these receptors in different ways, and the human evidence is thinner than the marketing. [Check the human data](https://cedclinic.com/minor-cannabinoids-human-evidence/) Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) ## Frequently Asked Questions Where are CB1 receptors located in the body? CB1 receptors are densest in the brain, specifically in the substantia nigra pars reticulata, globus pallidus, hippocampal formation, cerebellar molecular layer and association areas of frontal and limbic cortex. They are notably sparse in the brainstem nuclei controlling breathing and circulation. CB1 is also detectable at much lower levels in adrenal gland, heart, lung, prostate, uterus, ovary, testis, bone marrow, thymus and tonsil. Where are CB2 receptors located? CB2 is concentrated in immune tissue. Quantitative work on human tissue found CB2 expression in immune organs at 10 to 100 times the level of CB1, with spleen and tonsil carrying as much CB2 messenger RNA as the central nervous system carries CB1. Among blood cells the rank order was B cells, then natural killer cells, then monocytes, neutrophils, CD8 T cells and CD4 T cells. Are CB2 receptors present in the brain? This is unresolved. CB2 messenger RNA has been detected in brainstem neurons and in ventral tegmental area dopamine neurons, and CB2 agonists altered firing in those cells in mice. The protein evidence is weaker. Testing of four anti-CB2 antibodies against knockout mice in 2018 found none were highly specific for mouse CB2, so confident statements in either direction outrun the available data. What are the body’s own cannabinoids? The two best characterized endogenous ligands are anandamide, isolated from porcine brain in 1992, and 2-arachidonoylglycerol, identified independently in canine intestine and rat brain in 1995. Both are lipids synthesized on demand from membrane precursors rather than stored in vesicles, and both are broken down locally by dedicated enzymes, principally fatty acid amide hydrolase and monoacylglycerol lipase. Why is cannabis overdose rarely fatal? Anatomy explains most of it. The brainstem regions that regulate respiration and cardiovascular function carry very low densities of CB1 receptors, a point made in the 1990 study that first mapped the receptor. An excessive dose therefore produces disorientation, anxiety, tachycardia and vomiting rather than respiratory depression. This is a statement about lethality, not about safety, and does not apply to combinations with opioids or sedatives. How do endocannabinoids actually signal? Backward across the synapse. Work published in 2001 showed that endocannabinoids released by a depolarized hippocampal neuron travel to CB1 receptors on the presynaptic terminal supplying it and suppress transmitter release. This retrograde arrangement lets a cell turn down its own incoming signals. It is also why native endocannabinoid signaling is local and brief while an inhaled or swallowed cannabinoid is neither. Is there a third cannabinoid receptor? GPR55 is the leading candidate. A 2007 study found that GPR55 binds and is activated by cannabinoid ligands including anandamide and cannabidiol, and couples to different intracellular machinery than CB1 or CB2. The International Union of Pharmacology has not classified it as a cannabinoid receptor. Several other targets, including TRPV1 and peroxisome proliferator-activated receptors, respond to cannabinoids without being cannabinoid receptors. Does knowing receptor locations help choose a cannabis product? Less than product marketing suggests. THC is a partial agonist at both CB1 and CB2, and cannabidiol has low affinity for either and acts largely through other targets. No commercially available cannabis product selectively engages one cannabinoid receptor. The variables that genuinely change outcomes are dose, route of administration, timing and cannabinoid ratio, which is where a clinical conversation is better spent. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).